Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong. (4th May 2017)

• Record Type: Journal Article
• Authors: Zhou, Keary R.; Cheng, Ashley; Ng, W. T.; Kwok, T. Y.; Yip, Elton Y. P.; Yao, Rosa; Leung, P. Y.; Lee, V. W. Y.
• Is Part Of: Journal of medical economics. Volume 20:Number 5(2017)
• Page Start: 541
• Page End: 548
• Publication Date: 2017-05-04
• Subjects: Cost minimization analysis -- Gastric cancer -- Capecitabine -- 5-Fluorouracil based treatment; Medical care -- Cost control -- Periodicals; Medical economics -- Periodicals; 362.10941
• DOI: 10.1080/13696998.2017.1296452
• Languages: English
• ISSNs: 1369-6998

Abstract

Abstract: Background: EOX (epirubicin, oxaliplatin, Xeloda; capecitabine) and FOLFOX4 (5-fluorouracil (5-FU), leucovorin, oxaliplatin) are the common chemotherapy regimens used in the treatment of advanced gastric cancer (aGC) in Hong Kong. This study aimed to compare the costs of these therapies for aGC patients from both the healthcare and societal perspectives. It should be noted that, while FOLFOX4 is routinely administered in an outpatient setting in North America and Europe, inpatient setting is adopted in Hong Kong instead, incurring hospitalization cost as a result. Methods: Fifty-eight patients were identified from the electronic records in two public tertiary hospitals, with 45 and 13 receiving EOX and FOLFOX4 regimens, respectively. Healthcare cost was direct medical costs including drugs, clinic follow-up, hospitalization, diagnostic laboratories, and radiographs. Societal cost refers to indirect costs such as patient time and travel costs. Cost items were further classified as "expected" or "unexpected". All cost data was expressed in US dollars. Results: Patients in the EOX and FOLFOX4 arm received an average of 5.3 and 7.8 cycles of treatment, respectively. The capecitabine-based regimen group had a higher expected medication cost per cycle when compared to the 5-FU-based treatment group (US$290.3 vs US$66.9, p < .001), but lower expected hospitalization costs (US$76.9 vs US$1, 269.2, p < .001). The total healthcare cost and total societal cost per patient was reduced by 67.2% (US$5, 691.9 vs US$17, 357.4, p < .001) and 25.3% (US$3, 090.5 vs US$4, 135.1, p = .001), respectively, in the capecitabine-based regimen group. Sensitivity analyses based on full cycle regimen costs and net capecitabine or 5-FU/leucovorin costs still showed EOX to be less costly than FOLFOX4. Conclusion: The capecitabine-based regimen, EOX, was found to generate significant cost saving from both the healthcare and societal perspectives in regions in which FOLFOX4 is given in an inpatient setting.